The Changing Treatment Landscape of B Cell Malignancies

Ongoing Challenges in the Management of B-Cell Malignancies
February 11, 2020 – 
Before concluding his discussion on the management of B-cell malignancies, an expert shares insight on the ongoing challenges in this space.
B-Cell Malignancies: Evolving Role of Payers and Providers
February 11, 2020 – 
Specific considerations for the future roles of payers and care providers as the B-cell malignancy treatment landscape evolves.
B-Cell Malignancies: Cost and Integration of Novel Therapy
February 04, 2020 – 
Due to cost of novel therapeutic strategies, an expert shares insight on how these agents could be integrated into treatment pathways.
CLL and MCL: Factors in Selecting a BTK Inhibitor
February 04, 2020 – 
Homing in on specific Bruton tyrosine kinase inhibitors used to treat B-cell malignancies, an expert considers selecting one agent over another.
Considering BTK Inhibition's Role in Treating CLL and MCL
January 28, 2020 – 
A review of the rationale behind Bruton tyrosine kinase inhibitors and their role in managing B-cell malignancies.
B-Cell Malignancies: Coverage, Access, and Cost
January 28, 2020 – 
In-depth considerations for the coverage, access, and cost of novel therapeutic agents used to treat B-cell malignancies.
MCL and CLL: NCCN Guidelines and Treatment Options
January 21, 2020 – 
Expert insight on National Comprehensive Cancer Network guidelines with deference to chronic lymphocytic leukemia and mantle cell lymphoma.
An Overview of B-Cell Malignancies
January 21, 2020 – 
A comprehensive review of the individual diseases that constitute B-cell malignancies.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.